FDA "Successful Defense" Generic Exclusivity Policy Invalid - Mova Ruling
FDA's "successful defense" policy for awarding generic drugs exclusivity is invalid, the D.C. federal appeals court ruled April 14.
You may also be interested in...
Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials